A breakthrough in treating an aggressive form of prostate cancer could boost survival rates, according to new research.

By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...

A new study may have found a potentially easier, less disruptive and more effective way to treat the second leading cause of ...

The addition of apalutamide to androgen deprivation therapy before and after surgery improved outcomes among men with ...

Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the ris ...

A new blood test could help doctors identify whether a treatment for advanced prostate cancer is failing weeks earlier than ...

Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a side effect so debilitating that patients often refuse the life-saving ...

From radiopharmaceuticals to hypofractionated radiation therapy, one expert explained the current landscape of radiation treatments for prostate cancer. Radiopharmaceuticals, defined by the National ...

In a recent interview with CURE, Dr. Kai Tsao discussed treatment advancements for patients with prostate cancer. In a recent interview with CURE, Dr. Kai Tsao broke down current treatment ...

Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and death in late-stage studies. Read more at straitstimes.com. Read more at ...